SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

Applied Digital is trending with high anticipation for its upcoming earnings report, where the community expects strong guidance and updates on critical hyperscaler contracts to validate its AI infrastructure growth story. Positive developments regarding local government approvals for new data center projects are further fueling discussions, as investors eye the potential for a substantial short squeeze and a re-rating of the stock. The focus remains on the company's transition to high-performance computing leases and its expanding role in addressing the AI power bottleneck.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

MicroStrategy is seeing significant discussion as MSCI announced it will not exclude digital asset treasury companies from its global indexes for the upcoming February 2026 review, alleviating a major overhang. This decision is fueling bullish sentiment, with many anticipating a substantial short squeeze and a path to higher valuations, while bears remain focused on dilution risks and the stock's correlation to Bitcoin's sustained strength.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is capturing significant investor attention following its recent strategic acquisition of Ask Sage and substantial debt reduction, which strengthens its market position in secure AI solutions for defense and regulated sectors. The community is actively discussing the potential for imminent large government contracts, particularly with the TSA, driving strong bullish sentiment and expectations of a short squeeze, while also acknowledging recent share authorizations.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is experiencing significant market attention following commentary from NVIDIA's CEO regarding severe memory bottlenecks impacting AI infrastructure. This has ignited a passionate debate within the community, with many celebrating the stock's parabolic ascent as an "AI memory supercycle," while others express strong skepticism, labeling it an overvalued "speculative bubble." The rapid surge reflects the intense focus on how AI-driven data demand is impacting the broader memory and storage sector.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is trending with considerable discussion focused on its high borrow rate and extremely limited shortable shares, fueling anticipation for a significant short squeeze. The community is actively drawing parallels to its history of explosive, low-float runs and other highly speculative plays originating from the region.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is experiencing heightened conversation following its recent announcement regarding site selection for a pioneering fusion power plant, driving significant investor speculation. This development, alongside ongoing discussions surrounding former President Trump's geopolitical actions concerning Venezuela's oil and potential acquisition of Greenland, fuels a highly polarized community debate. Many view the fusion energy venture as a massive growth opportunity, while critics highlight the highly speculative nature of these initiatives and continued high short interest in the stock.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences (VTYX) is trending amidst reports that Eli Lilly ($LLY) is in advanced talks to acquire the company for over $1 billion, sparking widespread discussion about its valuation. The community is actively debating whether the rumored price adequately reflects Ventyx's promising NLRP3 inhibitor pipeline, which is seen as strategically valuable for addressing various inflammatory and metabolic conditions. This potential deal highlights the intense M&A activity in the biopharma sector for assets that could complement existing therapies and unlock new treatment paradigms.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is trending as the quantum computing sector buzzes with anticipation for the upcoming CES 2026 event, where the company's CMO is slated to speak, bolstered by recent news of a 100-qubit system deal in South Korea. Bulls are optimistic, pointing to IonQ's technological leadership and strategic partnerships as drivers for future growth, while bears emphasize concerns over high valuation and insider selling. The community remains divided between the long-term transformative potential of quantum technology and its current commercial viability.

Enovix Corp. engages in the design and development of silicon-anode lithium-ion batteries. The firm's proprietary 3D cell architecture increases energy density and maintains a high cycle life. It is also developing its 3D cell technology and production process for the electric vehicle and energy storage markets to help enable utilization of renewable energy. The company was founded by Mr. Harrold Jones Rust, III, Ashok Lahiri, and Murali Ramasubramanian in November 2006 and is headquartered in Fremont, CA.

Enovix Corporation

Enovix Corp

Enovix is trending amidst strong anticipation for CES 2026, with significant community discussion around potential product reveals showcasing its silicon-anode batteries in smartglasses or other devices, including rumored engagements with Honor and a major Silicon Valley customer. This comes alongside recent speculation of a substantial electrolyte supply agreement, fueling hopes for impending mass production and validation of its battery technology, crucial for the increasing power demands of AI-powered consumer electronics.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending amidst a surge of bullish community sentiment, with many anticipating a "next leg up" and speculating on a potential path towards the $1 milestone. Discussions are fueled by broader crypto market optimism, "altseason" expectations, and the belief that institutional interest could drive its value. However, some users express caution about potential retracements and market manipulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NextCure Shares Jump 15% After Private Placement Announcement

(RTTNews) - NextCure, Inc. (NXTC) rose 14.88% to $9.61, up $1.24, after announcing it has entered into a private placement of approximately $21.5 million, issuing 2,523,477 shares of common stock or...

Does NextCure (NXTC) Have the Potential to Rally 107.88% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in NextCure (NXTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

NextCure, Inc. stock surged nearly 45% in Thursday's extended trading session after the biopharma firm unveiled new preclinical results showing its experimental antibody may offer a more effective treatment for osteogenesis imperfecta (OI), a rare genetic condition also known as brittle bone disease.In studies using a well-established mouse model of OI, NextCure stated that its NC605 candidate improved bone strength and quality, and reduced fracture rates, outperforming current experimental treatments, such as anti-sclerostin.Key findings from the study:<ul style="list-style-type:circle;"><li>NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.</li><li>Fracture incidence was lower in mice treated with a surrogate antibody compared to those receiving anti-sclerostin or placebo.</li><li>NC605 showed the potential to both prevent bone loss and promote new, stronger bone formation.</li></ul>"There is currently no standard of care approved by the FDA for patients with OI," said Dr. Priyanka Kothari, Director of Translational Research at NextCure. "NC605 has the potential to provide significant therapeutic benefit for patients."On Stocktwits, <a href="https://stocktwits.com/symbol/NXTC">NextCure</a> was among the top 10 trending tickers late Thursday, with sentiment turning 'extremely bullish' (94/100) and hitting its highest level this year, while message volume spiked.&nbsp;NXTC's retail following on the platform also rose by 2% following the news.Still, NextCure stock has shed over 43% of its value this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/meme-stock-fever-hits-healthcare-triangle-stock/choGVbvR5vR">Meme Stock Fever Hits Healthcare: Nano-Cap HCTI More Than Doubles, Lifting Retail Mood To 2-Month High</a>

NextCure Stock Soars After-Hours On Promising Preclinical Data For Rare Bone Disease Treatment

NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.

Equity

NC605 boosted bone density and quality, including improved cortical thickness and reduced bone fragility.


Shares of NextCure, Inc. (NXTC) slumped 27% on Monday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/06/16/3099713/0/en/NextCure-and-Simcere-Zaiming-Announce-Strategic-Partnership-for-a-Novel-Antibody-Drug-Conjugate-Targeting-CDH6.html">announced</a> a strategic partnership with China-based Simcere Zaiming to develop a therapy for the treatment of solid tumors.Simcere Zaiming is an oncology-focused biopharmaceutical company and a subsidiary of Hong Kong-listed Simcere Pharmaceutical Group Ltd.The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors. This compound has demonstrated robust anti-tumor activity across multiple solid tumor models in preclinical studies.Antibody-drug conjugates (ADCs) are a class of targeted cancer therapies designed to deliver chemotherapy directly to cancer cells, minimizing harm to healthy cells.The drug is currently in early-stage testing in China. NextCure anticipates commencing clinical testing in the United States in the third quarter of 2025, with early-stage clinical data anticipated in the first half of 2026.While NextCure will gain global rights to SIM0505, excluding Greater China, Simcere Zaiming will retain rights there, the company said.Simcere Zaiming is eligible to receive payments of up to $745 million throughout the potential development phases. This includes upfront payment, development, regulatory, and sales milestone payments.The China-based company is also eligible to receive tiered royalties up to double digits on net sales outside of the Greater China territory.On Stocktwits, retail sentiment around NextCure rose from ‘bullish’ to ‘extremely bullish’ territory over the past 12 months while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_16_at_12_05_23_PM_png_99a749c3d2.webp" alt="NXTC's Sentiment Meter and Message Volume as of 12:05 p.m. ET on June 16, 2025 | Source: Stocktwits" width="627" height="66"><figcaption>NXTC's Sentiment Meter and Message Volume as of 12:05 p.m. ET on June 16, 2025 | Source: Stocktwits</figcaption></figure><a href="https://stocktwits.com/symbol/NXTC">NXTC stock</a> is down by about 39% this year and by about 65% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/abbvie-says-cancer-drug-failed-to-prolong-survival-in-late-stage-study/chlnHmLRRRA">AbbVie Says Cancer Drug Failed To Prolong Survival In Late-Stage Study: Retail’s On The Fence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

NextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% Decline

The newly announced partnership aims to develop SIM0505, a novel antibody-drug conjugate developed by Simcere Zaiming for the treatment of solid tumors. 

Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. With several peer companies in Phase 2 trials boasting market caps of over $500 million, Shuttle's valuation stands at just $4 million.<ul><li>Radiation therapy is a cornerstone of cancer treatment, with approximately 50% of cancer patients undergoing it during their illness. A sensitizer is a drug designed to enhance the effectiveness of radiation by making cancer cells more susceptible to damage while sparing healthy cells. This approach revolutionizes therapy by increasing tumor control and minimizing harmful side effects, particularly for aggressive cancers like glioblastoma. Shuttle Pharma’s Ropidoxuridine is at the forefront of this innovation. &nbsp;</li><li>Valuation discrepancies in the biotech sector highlight Shuttle Pharma’s incredible potential. While several peer companies in Phase 2 trials boast market caps exceeding $500 million, Shuttle’s valuation stands at just $4 million. This mismatch reflects a significant opportunity for investors, as Shuttle is already enrolling patients in its Phase 2 trial for Ropidoxuridine. &nbsp;</li><li>Founded by Georgetown University faculty, Shuttle Pharma is led by experienced scientists and executives with decades of oncology expertise. The management team includes individuals responsible for bringing successful cancer therapies to market, further bolstering its credibility.</li></ul>&nbsp;Shuttle Pharmaceuticals: Revolutionizing Radiation Therapy by Making it More Effective at Killing Cancer Cells while Sparing Healthy Cells<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/shuttle-pharmaceuticals/">Shuttle Pharmaceuticals (NASDAQ: SHPH)</a> is a clinical-stage biotech company specializing in therapies that enhance the efficacy of radiation therapy while minimizing side effects. Beyond Ropidoxuridine, Shuttle Pharma’s pipeline includes promising candidates like SP-2-225 and SP-1-303, along with diagnostic tools that could streamline FDA approval and open additional revenue streams.Dr. Anatoly Dritschilo, the company’s CEO, brings decades of experience as a radiation oncology leader and professor at Georgetown University. His tenure at the institution has cemented his reputation as an innovator in radiosensitization and therapeutic resistance strategies.&nbsp;Hope for Those Facing a Ruthless CancerGlioblastoma (GBM) is one of the deadliest cancers, with a five-year survival rate of just 6.9% and an average survival of eight months. It impacts cognition, mood, and independence, placing emotional and financial burdens on patients and families. With only a handful of FDA-approved treatments, GBM remains a significant challenge, but innovations like Shuttle Pharma’s Ropidoxuridine offer hope for better outcomes.&nbsp;Pipeline Overview and Flagship DrugShuttle Pharma’s pipeline includes:<ul><li>Ropidoxuridine (IPdR): Their flagship radiation sensitizer in Phase 2 trials for glioblastoma. As a sensitizer, it enhances the vulnerability of cancer cells to radiation while sparing healthy tissues, leading to improved therapeutic outcomes. The drug has received an Orphan Drug Designation, ensuring market exclusivity upon approval (3). Early data supports its safety and oral bioavailability, with promising mechanisms to sensitize cancer cells without harming normal tissues.</li><li>SP-2-225: A preclinical HDAC6 inhibitor targeting immune activation post-RT. HDAC6 inhibitors are emerging as a transformative class of drugs with the potential to improve tumor recognition by the immune system (4). This drug could have broad applications combined with radiation therapy and other immune therapies, addressing a large oncology market.</li><li>SP-1-303: Another preclinical asset targeting estrogen receptor-positive breast cancers, a subtype that represents a significant portion of all breast cancer diagnoses. Its unique mechanism of action and potential synergy with current hormonal treatments create substantial commercial potential.</li></ul><img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/shuttle_pharma_pipeline_8164d4c4cb.png" alt="shuttle-pharma-pipeline.png">&nbsp;Market Potential for Ropidoxuridine and Other CandidatesRadiation sensitizers represent a multi-billion-dollar opportunity. The global radiation therapy market is projected to grow significantly, reaching $14.18 billion by 2028 (2). Approximately 50% of all cancer patients undergo radiation therapy, amounting to a substantial number of patients annually in the US alone (1). A significant portion of these patients are treated with curative intent, offering a target market potentially worth billions for sensitizing agents.With glioblastoma as the initial target, Shuttle’s technology could eventually expand into other cancer types where radiation is a core treatment modality, such as lung, breast, and gastrointestinal cancers. By reducing radiation toxicity and improving tumor control, Ropidoxuridine could become an essential adjunct to standard cancer care.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/global_radiation_therapy_market_graph_9d83a88dbe.jpeg" alt="global-radiation-therapy-market-graph.jpeg">Simple Mechanism of Action and Proven SafetyRopidoxuridine acts as a prodrug, metabolized into IUdR upon ingestion. IUdR incorporates into cancer DNA, enhancing RT-induced DNA damage while sparing healthy cells.In layman’s terms, Ropidoxuridine is like a “homing beacon” for radiation therapy, guiding the radiation to attack cancer cells while avoiding healthy tissues. This straightforward and targeted approach significantly increases the likelihood of clinical success compared to more complex therapies.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/how_does_ropidoxuridine_work_17eaa74e99.png" alt="how-does-ropidoxuridine-work.png">Comparative Analysis: Valuation vs. PeersBiotech valuations often evolve significantly as companies progress through clinical trials. For Phase 1 assets, the average valuation tends to hover between $100 – $250 million, while Phase 2 assets range from $250 – $750 million (5). Currently valued at approximately $4 million, Shuttle Pharma is an outlier, suggesting it should be 25x higher based on similar Phase 2 comparables. If Ropidoxuridine demonstrates efficacy, the company could see valuations 100x higher, reflecting the upside potential.&nbsp;Similar Stage Comparisons: Phase 2 Enrollment<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/leap-therapeutics">Leap Therapeutics (NASDAQ: LPTX)</a><ul><li>Market Cap: Approximately $82 million</li><li>Focus: Antibody-based therapies targeting immune modulation in cancer.</li><li>Pipeline: DKN-01, currently in Phase 2 for gastric and gynecologic cancers&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.leaptx.com/pipeline/">(4)</a>.</li><li>Comparison Insight: Leap Therapeutics commands a valuation over 20x that of Shuttle Pharma, underscoring the latter’s deep undervaluation relative to its stage of development.</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/nextcure">NextCure (NASDAQ: NXTC)</a><ul><li>Market Cap: Approximately $23 million</li><li>Focus: Immune therapies targeting novel tumor-specific antigens.</li><li>Pipeline: NC318, currently in Phase 2 trials for advanced solid tumors.</li><li>Comparison Insight: NextCure reflects the market’s optimism for immune-oncology therapies in Phase 2 trials.</li><li>Demonstrated Efficacy Comparisons: Post-Positive Phase 2</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/kura-oncology">Kura Oncology (NASDAQ: KURA)</a><ul><li>Market Cap: Approximately $620 million</li><li>Focus: Precision oncology for genetically defined cancers.</li><li>Pipeline: Tipifarnib, demonstrating efficacy in Phase 2 for HRAS-mutant cancers&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://kuraoncology.com/pipeline/">(6)</a>.</li><li>Comparison Insight: Kura highlights the potential valuation growth when efficacy is shown in Phase 2 for a targeted therapeutic.</li></ul>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/adicet-bio">Adicet Bio (NASDAQ: ACET)</a><ul><li>Market Cap: Approximately $76 million</li><li>Focus: Allogeneic gamma-delta T cell therapies for oncology.</li><li>Pipeline: ADI-001, demonstrating Phase 2 efficacy in B-cell lymphomas.</li><li>Comparison Insight: Adicet underscores how valuation grows post-efficacy, aligning with Shuttle Pharma’s potential trajectory.</li></ul>&nbsp;An Accomplished Team Backed by Prestigious InstitutionsShuttle Pharma’s leadership is grounded in expertise, with key team members boasting extensive experience in oncology drug development:<ul><li>Dr. Anatoly Dritschilo: CEO and co-founder, a globally recognized radiation oncology expert with over 40 years of experience. Dr. Dritschilo has published extensively on radiation therapy and drug discovery and is an innovator in developing strategies for radiosensitization and therapeutic resistance.</li><li>Dr. Tyvin Rich: Medical Director with experience at MD Anderson and Harvard, specializing in radiation sensitizers.</li><li>Dr. Mira Jung: Scientific Director and co-founder, a professor of Radiation Medicine at Georgetown University.</li></ul>The rest of the team comprises an impressive roster of PhDs, MDs, and industry veterans with decades of combined experience developing oncology therapies and navigating FDA regulatory pathways.Strong Insider Ownership and Shareholder AlignmentWith 28.3% insider ownership, including a significant investment from the CEO, Shuttle Pharma’s management is deeply aligned with shareholder interests. This rare level of insider ownership reflects confidence in the company’s potential. High insider ownership ensures that decision-makers have “skin in the game,” aligning their financial interests with investors and creating trust in long-term value creation. Additionally, if clinical data supports efficacy, the small public float (2.9 million shares) positions the stock for dramatic price appreciation.Conclusion: The Undervalued Biotech to WatchShuttle Pharma’s small float, strong leadership, and groundbreaking focus on radiation sensitizers position it as one of the most undervalued opportunities in biotech. With a Phase 2 trial underway and a massive addressable market, Shuttle could redefine cancer treatment while offering exponential upside for investors. Comparisons to higher-valued peers only underscore the gap—and the potential for rapid revaluation if results prove successful.Shuttle Pharma’s other drug candidates, including SP-2-225 and SP-1-303, offer compelling bonuses for investors. These unique yet complementary assets could potentially expand Shuttle’s market reach in oncology. Additionally, the company’s diagnostic tools present a unique opportunity: they often have more streamlined FDA approval processes than therapeutics and could potentially be spun off as a standalone business, unlocking significant shareholder value.References<ol><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.cancer.org/cancer/managing-cancer/treatment-types/radiation/basics.html">American Cancer Society: Radiation Therapy Overview</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.researchandmarkets.com/report/radiation-therapy?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=kpswcb&amp;utm_campaign=1977747+-+Global+Radiation+Therapy+Market+with+Focus+on+LINAC%2c+2024+Market+Report%3a+A+%2414.18+Billion+Market+in+2028%2c+Registering+a+Projected+CAGR+of+6.75%25+During+2024-2028&amp;utm_exec=carimspi">Global Radiation Therapy Market Report</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=519016">FDA Orphan Drug Designation List</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.leaptx.com/pipeline/">Leap Therapeutics Corporate Pipeline</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC8854317/">Biotech Valuation Trends</a></li><li><a target="_blank" rel="noopener noreferrer nofollow" href="https://kuraoncology.com/pipeline/">Kura Oncology: Pipeline</a></li></ol>This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.Wealthy VC and its employees are not Registered Investment Advisors, Broker-Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Wealthy VC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and Wealthy VC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. Our website and newsletter are for entertainment purposes only. This website is NOT a source of unbiased information. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.Release of Liability: Through the use of this email and/or website advertisement, by viewing or using it, you agree to hold Wealthy VC, its operators, owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. Wealthy VC-sponsored advertisements do not purport to provide an analysis of any company’s financial position, operations or prospects and this is not to be construed as a recommendation by Wealthy VC or an offer or solicitation to buy or sell any security. WealthyVC and our controlling entity 1000724287 Ontario Ltd have been compensated USD $7,500 per month for six months for investor relations by Shuttle Pharmaceuticals Holdings, Inc.None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provided herein. Instead, Wealthy VC strongly urges you to conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D and all reports published on SEDAR if the company featured is Canadian. Wealthy VC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.The Private Securities Litigation Reform Act of 1995 provides investors with a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be “forward-looking statements”. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day’s closing price and the high of-day price during our promotional coverage.In preparing this publication, Wealthy VC has relied upon information supplied by various public sources and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this email and website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this email and website are believed to be reliable, however, Wealthy VC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of material facts from such advertisement. Wealthy VC is not responsible for any claims made by the companies advertised herein, nor is Wealthy VC responsible for any other promotional firm, its program or its structure.<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/disclaimer/">View Full Disclaimer</a>&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Here’s Why Shuttle Pharma is the Most Undervalued Biotech Stock in Our Coverage Universe

NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lie Ping Chen in September 2015 and is headquartered in Beltsville, MD.

Nextcure Inc

Physical AI Infrastructure

Power & Energy to Support Growth

Healthcare Value & Innovation

Other – Comment Below

As markets head into 2026, investors are debating whether the next phase favors speculation or real-world execution. With capital rotating toward infrastructure, energy, and undervalued sectors like healthcare, which area do you think will matter most for portfolios in the year ahead?

Which Theme Will Matter Most for Portfolios in 2026?

Current Price	$12.99
Prev Close	$13.60
Open	$13.59
Dividend Yield	0.00%
50-Day Moving Average	$11.45
Beta	0.63
Avg. Volume	38,488.55
PE Ratio	-0.54

52-Week High	$15.74
52-Week Low	$2.69
Market Capitalization	$47.68M
EPS (Annual)	-$23.88
Price to Book	1.47
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

NXTC
Nextcure Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NXTC News

NXTCNextcure Inc